Consensus Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
20.26 ^USD	-3.62%		-6.20%	-13.23%

Mar. 08	Akero Therapeutics Raises $367 Million From Share Offering	MT
Mar. 07	Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology	CI

Evolution of the average Target Price on Akero Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a719ff5ec898a994be8ff784088f00._W_ClH68XIepbYpHH7HN7ISr5xgtGMEBukquJV8B6sY.oj6o9xTGHsbPPL4DSsKktMrf0C1scfU30nj0cx14s5zOOKniFtQ4s_Ao3w~192af5a38b8d90f71a661edbc29e4c6c

Analyst Recommendations on Akero Therapeutics, Inc.

UBS Adjusts Akero Therapeutics Price Target to $42 From $39, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Raises Price Target on Akero Therapeutics to $50 From $43, Maintains Buy Rating	Mar. 05	MT
UBS Adjusts Akero Therapeutics Price Target to $39 From $83, Maintains Buy Rating	23-10-12	MT
Cantor Fitzgerald Cuts Price Target on Akero Therapeutics to $39 From $69, Maintains Overweight Rating	23-10-11	MT
Morgan Stanley Cuts Price Target on Akero Therapeutics to $33 From $70, Maintains Overweight Rating	23-10-11	MT
RBC Cuts Price Target on 89bio to $27 From $34 Amid 'Negative Read-Through' From 'Disappointing' Akero Data; Outperform, Speculative Risk Kept	23-10-11	MT
Cantor Fitzgerald Initiates Akero Therapeutics at Overweight With $69 Price Target	23-09-19	MT
Evercore ISI Raises Price Target on Akero Therapeutics to $60 From $50, Maintains Outperform Rating	23-09-13	MT
UBS Initiates Coverage on Akero Therapeutics With Buy Rating, $83 Price Target	23-08-28	MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	23-07-07	DJ
Morgan Stanley Raises Price Target on Akero Therapeutics to $70 From $65, Maintains Overweight Rating	23-06-12	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Keeps Buy Rating	23-06-07	MT
Canaccord Genuity Adjusts Price Target on Akero Therapeutics to $59 From $58, Maintains Buy Rating	23-05-17	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $62 From $64, Maintains Buy Rating	23-05-16	MT
Canaccord Genuity Adjusts Akero Therapeutics Price Target to $58 From $50, Maintains Buy Rating	23-03-20	MT
Morgan Stanley Upgrades Akero Therapeutics to Overweight From Equal Weight, $65 Price Target	23-01-27	MT
Morgan Stanley Adjusts Price Target on Akero Therapeutics to $40 From $30, Maintains Equalweight Rating	22-11-07	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Maintains Buy Rating	22-11-07	MT
Morgan Stanley Raises Price Target on Akero Therapeutics to $30 From $26, Reiterates Equalweight Rating	22-09-14	MT
Evercore ISI Upgrades Akero Therapeutics to Outperform From In-Line, Adjusts Price Target to $50 From $10	22-09-14	MT
Morgan Stanley Adjusts Akero Therapeutics Price Target to $26 From $29, Maintains Equalweight Rating	22-02-01	MT
Morgan Stanley Adjusts Akero Therapeutics' Price Target to $29 from $27, Keeps Equalweight Rating	21-11-15	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $62 from $64, Keeps Buy Rating	21-11-15	MT
Canaccord Genuity Adjusts Price Target on Akero Therapeutics to $49 From $46, Keeps Buy Rating	21-11-15	MT
AKERO THERAPEUTICS : Morgan Stanley Downgrades Akero Therapeutics to Equal-Weight Rating From Overweight, Price Target Adjusted to $27 From $63	21-10-19	MT